טוען...
Engineering CAR-T Cells for Improved Function Against Solid Tumors
Genetic engineering T cells to create clinically applied chimeric antigen receptor (CAR) T cells has led to improved patient outcomes for some forms of hematopoietic malignancies. While this has inspired the biomedical community to develop similar strategies to treat solid tumor patients, challenges...
שמור ב:
| הוצא לאור ב: | Front Immunol |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6217729/ https://ncbi.nlm.nih.gov/pubmed/30420856 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.02493 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|